Good I’ll progress the an morning, key quarter on the for made an hand remarks to and the thank the in XXXX. guidance financial us towards then joining up call providing during our by our take first over I’ll our today’s performance call. through before and priorities. update provide After update our we opening closing Peter the QX you walk followed everyone on by start we to for will line performance which, questions. to and
session Therapy. treatment to to U.S. U.S. primarily the year; the XX% NeuroStar XX% The first adoption drive good over XX% continue of Advanced in in growth and million, by driven we year increase NeuroStar was a quarter growth $XX.X prior start as the revenue was an Advanced Total of Therapy the revenue revenue.
ability order was year out strategy, to for continues drive offers growth our strategic Advanced of our resistant for adoption which do the to patients, fourth Our proven for our NeuroStar NeuroStar psychiatrists and to we a alternative our In focus treatment their patients call, execute Advanced serving we outcomes On our laid list of depression. with which Therapy. Therapy’s validate the quarter a clinical viable so, provided for XXXX. to priorities
NeuroStar system, development for Advanced driving other to stage the work generation in continue these markets. our the and and long-term of launch NeuroStar a selectively on and and efforts, priorities marketing next force expansion begin of As focus in to new international by our clinical increases treat all territories Therapy Taking sales continue which Japan the reminder, all are expansion evaluate goal trained the BDM of utilization, incremental of of filled to indications are is bringing sales XXXX, into force the we the system an we territories, to expansion of first In marketing quarter, as four XX order, of active. related in our the those efforts add fully these end year. of and to our and the our XX each total look in set
continue able to are confident a continue session feel new to the the very excited as subsequent very quality and about salespeople drive we be predictable of We to we sales attract system we growth pull-through and result. in that can treatment
generate with TV first the a of ad our end learnings continued the most most to recently far the we campaigns. launched awareness, campaign stage, with insight improved been sales we at overall touch conversions have practice DTC know leads launched Therapy. and the turning and addition effective speed In psychiatrist of increase per of XXXX, for on results we quarter. requests we excellent we Advanced completed the Leveraging a seen the way ad focus expansion campaigns so campaigns of significant a importance In with we NeuroStar point, we cost appointment system to that a psychiatrist. and follow-up. patient into the those Each patient marketing utilization. ad optimized these have undergoing utilize effectively nationwide viewer our force, patients’ patient have a The provided to managing in contact a duration get at traffic, spend television patient multiple conversion. which into practice drive to to marketing Web increases treatment a of At this frequency, gained and campaign, campaign insight the patient ultimately the greater into our In further of
respond TV will patients are demand we to We to continue each improve efficient increased iteration, the that to create at more optimistic campaign. convert and rate the ability with who our
is second for increases. long-term utilization drive year priority the to Our strategic
or NeuroStar continue consultants we consultants, training the and clinical the will practice customers or CTC’s, to utility clinical have noted number and previously, order maximize we Advanced of our increase to patients. for As in Therapy CPC’s, of
based system XXXX. the the to Our goal CTC’s and in incremental territories on with add and distribution sales is additional CPC’s CPC’s six of up to five an system an for XXXX uneven keep new optimize sales
CPC’s we CTC’s quarter, six the hired for of and During the five the of ahead five the year. slightly our expectations of all first
of development our Another next of priorities NeuroStar one our generation launch strategic is system. future and the
early the stages multi-year NeuroStar process the system. next to in iteration create of We’re a of
clinical and research customer During of that pleased the development to starts begun am the goal voice we to system our completed that position both we’ve advancing we’ve look leadership our that and with capabilities towards of as and settings. by we continuingly our This research maintain product initiative I quarter, process. our from and first drive continue industry use to fundamental share in
the system. for work begin fourth Our XXXX Advanced clinical the to expansion use stage the NeuroStar priority Therapy for strategic to for is set of for indications
and is this clinical later This of building team the build this our of function. the trials focus and and current out clinical with nicely Our out advance I’m is brining on with PTSD year science on team into the pleased we’re planned bipolar. FDA talent discussions
for Our of is prudent the global final expansion the priority strategic our year footprint.
commercial focus is on Japan. near-term Our launch the in
yen in Health, continuum expected on March, provide announced facilities Obtaining a critical implementing a and XXXX. to Japanese approval will XX,XXX be is per As market Teijin strategy. treatment affect Therapy and to our to treatment much psychiatric NeuroStar for segmentation at single services reimbursement will the cover that Council XXX which largest provide out-patient with Labor facilities and alternative The Welfare in healthcare a and to Japan’s market patients. rate into system, to their approved Japan largest by the June and approximately psychiatrists outpatient in-patient needed Japan. milestone reimbursement comprehensive NeuroStar Pharmaceuticals, facilitates Japan, Central X, Advanced affordable Therapy in-patient approval distribution MDD treated or The reimbursement for of payer centers Ministry health go-to-market Medial Insurance in of initial partner, has expected with reimbursement aligns the for at go NeuroStar The to Advanced these session. recommendation Japan’s is ability in most is reimbursement the the into about Initially, Therapy. our have patients Social and facilities Advanced mental
approximately trained. have today, qualifying facilities been of As from doctors XX the
of process, the physician by part a be Teijin. both by the approval JSPN needs product and to As trained
market we there lower a collect and of While for the Japan. than are commercializing note in U.S., comfortable economic is product us the that to didn’t in the clinical I would level this data that level reimbursement supports process come launch few the the as we years to. the number increase that try facilities both utilize sell will as the potentially in next to over a of to can increase to subsequent Teijin level well Japanese of reimbursement
and hand While maintain position. the in in ability very discuss excited drive but our grow to we Overall, in the about our I we leadership market, do Teijin now first over efforts like revenue in remain as about would sales will the beyond performance. Japanese not to strong and market Peter enthusiastic and our quarter continue to revenue made financial and progress to the are XXXX anticipate top we to growth call we material mature. line anticipate that XXXX the business marketing
